

Supplementary Table 5 – Outcomes of interest

Author	Primary/ Secondary	Outcome	Intervention Arm		Control Arm		p- Value
			N	Statistic	N	Statistic	
Overall Survival							
Urashima (2019)	Secondary	Overall Survival (5 Years)	251	82% ^b	166	81% ^b	0.83
Urashima (2019)	Primary	Relapse-Free Survival (5 Years)	251	77% ^b	166	69% ^b	0.18
Urashima (2019)	Secondary	Relapse (5 Years)	251	NR	166	NR	0.21
Urashima (2019)	Secondary	Cancer-Specific Death (5 Years)	251	NR	166	NR	0.80
Urashima (2019)	Secondary	Non-Cancer Death (5 Years)	251	NR	166	NR	0.44
Post-Operative Mortality							
Haji.-Ketab. (2021) ^a	Secondary	Mortality Rate (6 Months)	30	0% (0/30)	30	0% (0/30)	1.000
Naguib (2021)	Secondary	In-Hospital Mortality	45	4.4% (2/45)	41	9.8% (4/41)	0.418
Parekh (2018)	Secondary	Survival (90 Days)	33	94% (31/33)	35	94% (33/35)	1.000
Urashima (2019)	Secondary	Overall Survival (90 Days)	251	100% ^c	166	99% ^c	NR ^c
Length of Hospital Stay (LOS)							
Barker (2021)	Secondary	LOS (Days)	75	8.6 ± 5.3	75	8.0 ± 7.4	0.35
Cerit (2018)	Secondary	LOS (Days)	68	8.1 ± 2.3	68	7.9 ± 2.1	0.891
Genser (2013)	Secondary	LOS (Days)	111	2.2 ± 0.9	108	2.3 ± 1.4	0.65
Haji.-Ketab. (2021) ^a	Secondary	LOS (Days)	30	5 (4-6.25)	30	8 (5-9.25)	0.008
Hao (2021)	Secondary	LOS in RDP ≤70% Subgroup (Days)	44	4.79 ± 1.42	44	4.42 ± 1.93	NS ^f

Hao (2021)	Secondary	LOS in RDP >70% Subgroup (Days)	47	5.06 ± 1.51	47	4.85 ± 1.52	NS ^f
Naguib (2021)	Primary	LOS (Days)	45	8 ± 2.2	41	9.5 ± 3.9	0.033
Parekh (2018)	Secondary	LOS (Days)	33	13 (11-23)	35	13 (10-20)	0.739
Rowe (2018)	Secondary	LOS (Days)	72	2 (2-2)	78	2 (2-3)	0.16
Length of ICU Stay (LOS-ICU)							
Barker (2021)	Secondary	LOS-ICU (Days)	75	3.4 ± 4.2	75	2.9 ± 4.8	0.22
Haji.-Katab. (2021) ^a	Secondary	LOS-ICU (Days)	30	1 (0-1.25)	30	2 (1-4.25)	0.010
Naguib (2021)	Primary	LOS-ICU (Hours)	45	54.5 ± 25.4	41	76.3 ± 52	0.044
Parekh (2018)	Secondary	LOS-ICU (Days)	33	5 (3-10)	35	4 (3-6)	0.052
Quality of Life (QoL)							
Aberg (2015)	Primary	SF-36 QoL - Physical (12 Months)	66	49 (39-53)	69	51 (41-55)	0.317
Aberg (2015)	Primary	SF-36 QoL - Mental (12 Months)	66	53 (43-57)	69	52 (42-57)	0.868
De Bruyn (2020)	Secondary	CDAI QoL (Change: Pre-op to 6 Months)	72	-62 (12) ^d	71	-82 (12) ^d	0.24
De Bruyn (2020)	Secondary	EQ-5D QoL (Change: Pre-op to 6 Months)	72	15.5 (2.3) ^d	71	13.1 (2.4) ^d	0.48
De Bruyn (2020)	Secondary	SF-36 QoL (Change: Pre-op to 6 Months)	72	10.9 (1.3) ^d	71	11.4 (1.4) ^d	0.77
De Bruyn (2020)	Secondary	IBDQ QoL (Change: Pre-op to 6 Months)	72	24.9 (3.7) ^d	71	31.1 (3.8) ^d	0.25
Other Outcomes							
Barker (2021)	Secondary	Serious Adverse Event (6 Months)	69	10.1% (7/69)	67	9.0% (6/67)	0.81

Eslami (2021)	Primary	Acute Kidney Injury (In-Hospital)	50 12% (6/50)	61 16% (10/61)	0.1
Krasowska (2019)	Primary	Pain Severity (4 Weeks)	18 2.83 (0.51) ^d	21 3.29 (0.37) ^d	NR ^e
Naguib (2021)	Secondary	Hospital Acquired Infection	45 35.6% (16/45)	41 56.1% (23/41)	0.017
Naguib (2021)	Secondary	Myocardial Infarction	45 35.6% (16/45)	41 34.1% (14/41)	0.831
Naguib (2021)	Secondary	Severe Bleeding	45 15.6% (7/45)	41 12.2% (5/41)	0.653
Parekh (2018)	Secondary	Acute Respiratory Distress Syndrome	33 12% (4/33)	35 11% (4/35)	1.00 ^h
Slobogean (2020)	Primary	Complication Rate (12 Months) ^e	45 24.4% (11/45)	41 31.7% (13/41)	0.92

Outcomes are classified as primary or secondary, as reported by the objectives of each study. Data are reported as Mean \pm Standard Deviation; Median (Interquartile Range); or % (n/N), unless stated otherwise. Bold p-values are significant at $p < 0.05$. ^a Hajimohammedbrahim-Ketabforoush. ^b Nelson-Aalen estimate. ^c Rates were extracted from a Nelson-Aalen survival curve at 90 days; the study did not report a p-value for 90-day survival but found no significant difference in overall survival rates. ^d Reported as Mean (Standard Error) ^e Patient-important complications. ^f The study reported a single p-value for a comparison across the four groups (i.e. defined by RDP and the intervention), which was non-significant. ^g The study did not report a p-value, but the difference between groups was not indicated to be statistically significant on the associated figure. ^h The study did not report a p-value; hence, this was calculated using a Fisher's exact test. NR=Not Reported; RDP= Relative decline in serum parathyroid hormone.